We have a replacement

Gilyarov M.Yu.

Михаил Юрьевич Гиляров

врач-кардиолог, д.м.н., профессор

SPIN РИНЦ: 7713-6726
Scopus AuthorID: 6506741565
ResearcherID: Q-2119-2017
ORCID: 0000-0002-2870-3301

У нас замена

Авторы:

Гиляров М.Ю.

Подробнее об авторах

Журнал: Non nocere. Новый терапевтический журнал. 2026;(1‑2): 78‑83

Прочитано: 103 раза

Связаться с автором

Оглавление

Как цитировать:

Гиляров М.Ю. У нас замена. Non nocere. Новый терапевтический журнал. 2026;(1‑2):78‑83.
Gilyarov MYu. We have a replacement. Non Nocere. New Therapeutic Journal. 2026;(1‑2):78‑83. (In Russ.)

Использование инфографики авторами научных работ

Резюме / Abstract:

Побочные эффекты статинов и возможные альтернативы в гиполипидемической терапии.

Авторы / Authors:

Михаил Юрьевич Гиляров

врач-кардиолог, д.м.н., профессор

SPIN РИНЦ: 7713-6726
Scopus AuthorID: 6506741565
ResearcherID: Q-2119-2017
ORCID: 0000-0002-2870-3301

Закрыть метаданные

Литература / References:

Cholesterol Treatment Trialists’ Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022 Sep 10;400(10355):832-845. https://doi.org/10.1016/S0140-6736(22)01545-8
Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):390-399. https://doi.org/10.1161/CIRCOUTCOMES.111.000071
Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018 Jul 14;39(27):2526-2539. https://doi.org/10.1093/eurheartj/ehy182
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010 Feb 27;375(9716):735-742. https://doi.org/10.1016/S0140-6736(09)61965-6
Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22;305(24):2556-2564. https://doi.org/10.1001/jama.2011.860
Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017 Oct 28;390(10106):1962-1971. https://doi.org/10.1016/S0140-6736(17)32290-0
Lymperopoulou C, Kandarakis SA, Tzanaki I, Mylona I, Xanthos T, Agouridis AP. The Effect of Statins on Ocular Disorders: A Systematic Review of Randomized Controlled Trials. Pharmaceuticals (Basel). 2023 May 7;16(5):711. https://doi.org/10.3390/ph16050711
Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke. 2008 Feb;39(2):497-502. https://doi.org/10.1161/STROKEAHA.107.488791
Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011 Nov 15;124(20):2233-2242. https://doi.org/10.1161/CIRCULATIONAHA.111.055269
Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. Circulation. 2019 Sep 17;140(12):992-1003. https://doi.org/10.1161/CIRCULATIONAHA.118.039415
Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023 Apr 13;388(15):1353-1364. https://doi.org/10.1056/NEJMoa2215024
Iannuzzo G, Kamboj G, Barman P, Dongare S, Jawla S. Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials. Atheroscler Plus. 2024 Oct 17;58:24-37. https://doi.org/10.1016/j.athplu.2024.10.001